When Democrats rammed through the Inflation Reduction Act during the days they controlled all of Washington, D.C., it ignited ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Novartis will pay $150 million upfront to Schrödinger, in a pact announced Tuesday to work together on several preclinical ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

The firm's chief scientific officer called the achievement "a major milestone for Spirovant and for the cystic fibrosis ...